The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Irritable Bowel Syndrome
IBS or endometriosis?
- Type 2 diabetes: sarcopenia and frailty
How can the breakdown of skeletal muscles be stopped?
- Cholangiocarcinoma
Modern molecular diagnostics and targeted therapy options
- Treatment resistant depression
Esketamine nasal spray as monotherapy? New for treatment-resistant depression
- Analysis of SNVCS data from the period 2005-2022
TBE vaccination for children and adolescents in Switzerland
- Tuberculosis
Detecting diabetes in TB patients early and efficiently
- Trichophyton indotineae
Terbinafine-resistant dermatophytoses are on the rise in Central Europe
- Peristomal skin health